A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

Trial Profile

A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Nov 2017 According to a Merck AG media release, results from this trial will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
    • 21 Apr 2017 Planned End Date changed from 17 Sep 2018 to 1 Dec 2018.
    • 21 Apr 2017 Planned primary completion date changed from 15 Mar 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top